The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis

Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma and commonly used induction immunochemotherapies include the anti-CD20 antibody rituximab. However, efficacy data for rituximab regarding overall survival (OS) in first line MCL therapy remain conflicting. We report long-term outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Luca, Jiang, Linmiao, Bittenbring, Joerg Thomas, Huebel, Kai, Schmidt, Christian, Duell, Johannes, Metzner, Bernd, Krauter, Juergen, Glass, Bertram, Huettmann, Andreas, Schaefer-Eckart, Kerstin, Silkenstedt, Elisabeth, Klapper, Wolfram, Hiddemann, Wolfgang, Unterhalt, Michael, Dreyling, Martin, Hoster, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492741/
https://www.ncbi.nlm.nih.gov/pubmed/37552322
http://dx.doi.org/10.1007/s00277-023-05385-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492741/
https://www.ncbi.nlm.nih.gov/pubmed/37552322
http://dx.doi.org/10.1007/s00277-023-05385-1

Ejemplares similares